Data show that as of the evening of April 6, 25 pharmaceutical companies have disclosed the first quarter performance forecast. Among them, 22 are pre happy, accounting for more than 80%. Covid-19’s performance in the field of detection and biological products has increased significantly. In addition, a number of pharmaceutical companies said in the first quarter performance forecast that there were sufficient orders and booming production and marketing.
net profit of companies increased by more than 100%
Among the 25 pharmaceutical companies that disclosed the first quarterly report, Hangzhou Alltest Biotech Co.Ltd(688606) , Baotou Dongbao Bio-Tech Co.Ltd(300239) , Porton Pharma Solutions Ltd(300363) , Tonghua Dongbao Pharmaceutical Co.Ltd(600867) , Guangdong Hybribio Biotech Co.Ltd(300639) , Zhejiang Conba Pharmaceutical Co.Ltd(600572) .
Hangzhou Alltest Biotech Co.Ltd(688606) is the company with the largest year-on-year increase in net profit in the first quarter. The company expects to realize the net profit attributable to the owners of the parent company from 1.03 billion yuan to 1.19 billion yuan in the first quarter, with a year-on-year increase of 585.40% to 691.87%; The net profit deducted from non profit was 1.025 billion yuan to 1.185 billion yuan, with a year-on-year increase of 597.74% to 706.70%. The company said that during the reporting period, the company’s covid-19 testing business orders continued to maintain a stable growth, resulting in a large-scale increase in the company’s performance in the first quarter of 2022 compared with the same period last year.
The first quarter performance in the field of biological products was also bright. “Insulin leader” Tonghua Dongbao Pharmaceutical Co.Ltd(600867) expects to realize a net profit of 817 million yuan attributable to shareholders of Listed Companies in the first quarter, with a year-on-year increase of 142.63%; “Vaccine leader” Chongqing Zhifei Biological Products Co.Ltd(300122) expects the net profit attributable to shareholders of Listed Companies in the first quarter to be 1.783 billion yuan to 1.97 billion yuan, with a year-on-year increase of 90% – 110%.
sufficient orders
A number of pharmaceutical companies said in the first quarter performance forecast that there were sufficient orders and booming production and sales.
Porton Pharma Solutions Ltd(300363) it is estimated that the operating revenue in the first quarter will reach 1.357 billion yuan to 1.466 billion yuan, with a year-on-year increase of 150% to 170%; The net profit attributable to the shareholders of the listed company was 326 million yuan to 344 million yuan, with a year-on-year increase of 270% to 290%; The non net profit attributable to shareholders of listed companies increased from 324 million yuan to 339 million yuan, with a year-on-year increase of 330% – 350%.
Porton Pharma Solutions Ltd(300363) said that benefiting from the high prosperity of cdmo industry, the company’s customer pipelines and product pipelines have been continuously expanded and enriched. In the first quarter, the company’s orders on hand grew strongly, and the major orders received by the company in the early stage were delivered smoothly in succession during the reporting period.
Zhejiang Hisoar Pharmaceutical Co.Ltd(002099) it is estimated that the net profit attributable to the shareholders of the listed company in the first quarter was 857819 million yuan to 103 million yuan, an increase of 50% to 80% year-on-year; The net profit attributable to shareholders of listed companies was 828139 million yuan to 999703 million yuan, with a year-on-year increase of 49.09% to 79.98%.
Zhejiang Hisoar Pharmaceutical Co.Ltd(002099) said that during the reporting period, the company’s industrial chain optimization and new product layout were effective, and its performance increased steadily. The company seized the opportunity to release production capacity and increase sales. In particular, the leading products in the pharmaceutical sector have achieved prosperous production and sales, sufficient orders and higher unit prices, overcome the adverse effects of rising raw material prices and exchange rate fluctuations, and gradually improve their profitability.
